Paper Details

  1. Home
  2. Paper Details

Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

Author: CollignonJoelle, JerusalemGuy, RoriveAndree

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Everolimus is a drug that inhibits the mTOR pathway, a pathway that is involved in cell growth and proliferation. This review discusses the use of everolimus in treating breast cancer. It showed a statistically significant improvement in progression-free survival in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.
Paper Details　
Original Abstract of the Article :
Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemesta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000187/

データ提供：米国国立医学図書館（NLM）

mTOR Inhibitors: A New Weapon in the Fight Against Breast Cancer

This study delves into the promising role of mTOR inhibitors in treating breast cancer, focusing on everolimus, a drug that has been approved for patients with estrogen receptor-positive, HER2-negative advanced breast cancer. Imagine it as a group of explorers searching for a hidden oasis in the desert of cancer – everolimus offers a new strategy in the fight against this disease.

Targeting Cancer Cells with mTOR Inhibitors

Everolimus, an mTOR inhibitor, works by blocking a specific signaling pathway that is often overactive in cancer cells. It's like interrupting a communication network that is fueling the growth of cancer cells. This research explores the potential of everolimus to slow down tumor growth and improve patient outcomes.

A New Hope in the Desert of Breast Cancer

This research offers a glimmer of hope for patients battling breast cancer. Everolimus has shown promising results in clinical trials, demonstrating its potential to prolong survival and improve the quality of life for patients with advanced breast cancer. It's like discovering a new source of water in the desert – a lifeline for those facing a difficult battle.

Dr. Camel's Conclusion

This research highlights the exciting potential of mTOR inhibitors, particularly everolimus, as a new weapon in the fight against breast cancer. It's a testament to the ongoing progress in cancer research and offers a beacon of hope for those seeking effective treatments.

Date :
  1. Date Completed 2014-06-24
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24833916

DOI: Digital Object Identifier

PMC4000187

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.